Search | OpenScholar

Search results

374 results found

Impact of non-motor symptoms in Parkinson's disease: a PMDAlliance survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.

Publication: Journal Article

Hermanowicz, N, SA Jones, and RA Hauser. 2019. “Impact of Non-Motor Symptoms in Parkinson’s Disease: A PMDAlliance Survey. Neuropsychiatr Dis Treat 2019;15:2205-2212.”. Neuropsychiatry Dis Treat.

Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci 2018;389:10-16.

Publication: Journal Article

“Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The Nosology of Tardive Syndromes. J Neurol Sci 2018;389:10-16.”. 2018. J Neurol Sci.

Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. J Neurol Sci 2017;373:116-123.

Publication: Journal Article

Tetrud, J, P Nausieda, D Kreitzman, GS Liang, A Nieves, AP Duker, RA Hauser, et al. 2017. “Conversion to Carbidopa and Levodopa Extended-Release (IPX066) Followed by Its Extended Use in Patients Previously Taking Controlled-Release Carbidopa-Levodopa for Advanced Parkinson’s Disease. J Neurol Sci 2017;373:116-123.”. J Neurol Sci .

KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017;174:476-484.

Publication: Journal Article

Hauser, RA, SA Factor, SR Marder, MA Knesevich, PM Ramirez, , J Burke, GS Liang, and CF O’Brien. 2017. “KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry 2017;174:476-484.”. Am J Psychiatry.

A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. Mov Disord 2017;32:783-789.

Publication: Journal Article

Olanow, CW, K Kieburtz, M Leinonen, N Giladi, RA Hauser, OS Klepiskaya, DL Kreitzman, et al. 2017. “A Randomized Trial of a Low-Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease. Mov Disord 2017;32:783-789.”. Mov Disord.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology 2017;88:2003-2010.

Publication: Journal Article

Fernandez, HH, SA Factor, RA Hauser, J Jimenez-Shahed, and . 2017. “Randomized Controlled Trial of Deutetrabenazine for Tardive Dyskinesia: The ARM-TD Study. Neurology 2017;88:2003-2010.”. Neurology.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord 2017;32:1701-1709.

Publication: Journal Article

Oertel, W, K Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, R Ehret, et al. 2017. “Randomized, Placebo-Controlled Trial of ADS-5102 (amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 3). Mov Disord 2017;32:1701-1709.”. Mov Disord.

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol 2016;15:954-66.

Publication: Journal Article

Espay, AJ, PA LeWitt, RA Hauser, A Merola, M Masellis, and AE Lang. 2016. “Neurogenic Orthostatic Hypotension and Supine Hypertension in Parkinson’s Disease and Related Synucleinopathies: Prioritisation of Treatment Targets. Lancet Neurol 2016;15:954-66.”. Lancet Neurol.

Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Mov Disord 2016;31:1489-1496.

Publication: Journal Article

Rascol, O, RA Hauser, F Stocchi, CJ Fitzer-Attas, Y Sidi, V Abler, CW Olanow, and AFU Investigators. 2016. “Long-Term Effects of Rasagiline and the Natural History of Treated Parkinson’s Disease. Mov Disord 2016;31:1489-1496.”. Mov Disord.

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov Disord 2016;31:1356-65.

Publication: Journal Article

LeWitt, PA, RA Hauser, DG Grosset, F Stocchi, MH Saint-Hilaire, A Ellenbogen, M Leinonen, et al. 2016. “A Randomized Trial of Inhaled Levodopa (CVT-301) for Motor Fluctuations in Parkinson’s Disease. Mov Disord 2016;31:1356-65.”. Mov Disord.